TN2009000085A1 - Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3 - Google Patents

Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3

Info

Publication number
TN2009000085A1
TN2009000085A1 TN2009000085A TN2009000085A TN2009000085A1 TN 2009000085 A1 TN2009000085 A1 TN 2009000085A1 TN 2009000085 A TN2009000085 A TN 2009000085A TN 2009000085 A TN2009000085 A TN 2009000085A TN 2009000085 A1 TN2009000085 A1 TN 2009000085A1
Authority
TN
Tunisia
Prior art keywords
inhibitors
pyrido
pyrimidinone derivatives
derivatives
pyrimidinone
Prior art date
Application number
TN2009000085A
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip 2Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000085A1 publication Critical patent/TN2009000085A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des dérivés de 4-méthylpyridopyrimidinone nouveaux de formule (I). leurs sels, leur synthèse, et leur utilisation comme inhibiteurs de la phosphoinositide -3- kinase alpha (PI3-ka).
TN2009000085A 2006-09-15 2009-03-13 Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3 TN2009000085A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (fr) 2006-09-15 2007-09-03 Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3

Publications (1)

Publication Number Publication Date
TN2009000085A1 true TN2009000085A1 (fr) 2010-08-19

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000085A TN2009000085A1 (fr) 2006-09-15 2009-03-13 Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3

Country Status (42)

Country Link
US (3) US7696213B2 (fr)
EP (1) EP2074122B9 (fr)
JP (1) JP4718637B2 (fr)
KR (1) KR101099926B1 (fr)
CN (1) CN101573358B (fr)
AP (1) AP2710A (fr)
AR (1) AR062785A1 (fr)
AT (1) ATE514695T1 (fr)
AU (1) AU2007297212B8 (fr)
BR (1) BRPI0716749B8 (fr)
CA (1) CA2663401C (fr)
CL (1) CL2007002682A1 (fr)
CR (1) CR10662A (fr)
CU (1) CU23783B7 (fr)
CY (1) CY1111911T1 (fr)
DK (1) DK2074122T5 (fr)
DO (1) DOP2009000039A (fr)
EA (1) EA016388B1 (fr)
ES (1) ES2366489T3 (fr)
GE (1) GEP20115306B (fr)
GT (1) GT200700077A (fr)
HK (1) HK1138589A1 (fr)
HN (1) HN2007000267A (fr)
HR (1) HRP20110621T2 (fr)
IL (1) IL197243A (fr)
MA (1) MA30709B1 (fr)
ME (1) MEP8009A (fr)
MX (1) MX2009002927A (fr)
MY (1) MY146420A (fr)
NI (1) NI200900032A (fr)
NO (1) NO342357B1 (fr)
NZ (1) NZ575167A (fr)
PE (1) PE20080670A1 (fr)
PL (1) PL2074122T3 (fr)
PT (1) PT2074122E (fr)
RS (2) RS20090104A (fr)
SI (1) SI2074122T1 (fr)
TN (1) TN2009000085A1 (fr)
TW (1) TWI334353B (fr)
UY (1) UY30588A1 (fr)
WO (1) WO2008032162A1 (fr)
ZA (1) ZA200901477B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101099926B1 (ko) 2006-09-15 2011-12-28 화이자 프로덕츠 인코포레이티드 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도
WO2008124161A1 (fr) * 2007-04-10 2008-10-16 Exelixis, Inc. Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
MX2011000440A (es) * 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (fr) 2008-08-20 2010-02-25 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
EP2326626B1 (fr) * 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Dérivés de pyridine et de pyrimidine substitués par éthényle et leur utilisation dans le traitement d'infections virales
WO2010039740A1 (fr) * 2008-09-30 2010-04-08 Exelixis, Inc. Inhibiteurs de pyridopyrimidinone de la pi3 kinase α et de la mtor
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
TW201500358A (zh) 2010-12-16 2015-01-01 Hoffmann La Roche 三環pi3k抑制劑化合物及其使用方法
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
AU2012333092B2 (en) 2011-08-31 2016-04-21 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
BR112017006113A8 (pt) 2014-10-10 2018-04-24 Pfizer usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
KR102068423B1 (ko) 2015-06-04 2020-01-20 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3481822B1 (fr) 2016-07-06 2022-06-22 The Regents of The University of Michigan Inhibiteurs multifonctionnels des voies biologiques de mek/pi3k et mtor/mek/pi3k et procédés thérapeutiques les utilisant
CR20190062A (es) * 2016-08-15 2019-05-22 Pfizer Inhibidores de cdk2/4/6
CN110049783A (zh) * 2016-12-14 2019-07-23 塔弗达治疗有限公司 Hsp90-靶向缀合物及其制剂
WO2019157516A1 (fr) 2018-02-12 2019-08-15 resTORbio, Inc. Polythérapies
JP7382353B2 (ja) 2018-06-15 2023-11-16 ヤンセン ファーマシューティカ エヌ.ベー. ラパマイシン類似体およびその使用
CA3124574A1 (fr) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Inhibiteurs de kinases cycline-dependantes
WO2020140053A1 (fr) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Inhibiteurs de kinases dépendantes des cyclines
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
EP4069223A4 (fr) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV Analogues de la rapamycine et leurs utilisations
WO2021139775A1 (fr) * 2020-01-10 2021-07-15 江苏先声药业有限公司 Composé de pyridone et son application
WO2022075974A1 (fr) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Inhibiteurs cycliques de trex1
BR112023009531A2 (pt) 2020-11-18 2023-10-03 Deciphera Pharmaceuticals Llc Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
CA3238551A1 (fr) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methodes et compositions pour traitement du cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE60144322D1 (de) 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
RU2004133811A (ru) 2002-04-19 2005-04-20 Смитклайн Бичам Корпорейшн (US) Новые соединения
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (fr) 2003-04-02 2004-10-21 Imclone Systems Incorporated Derives de 4- fluoroquinolone et leur utilisation comme inhibiteurs de kinase
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
EP1648889B1 (fr) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Sel d'isethionate d'un inhibiteur selectif de la cdk4
EP1660087A2 (fr) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Derives de quinolinone en tant qu'inhibiteurs de c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PT1713806E (pt) 2004-02-14 2013-08-27 Irm Llc Compostos e composições como inibidores da proteína quinase
CA2555724A1 (fr) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
EP1740184A1 (fr) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinaisons d'inhibiteurs de transduction de signaux
WO2005105097A2 (fr) 2004-04-28 2005-11-10 Gpc Biotech Ag Derives de pyridopyrimidine
BRPI0510560A (pt) * 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
BRPI0511065A (pt) 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
WO2006021547A1 (fr) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones utilisees en tant qu'inhibiteurs des plk (polo-like-kinases)
WO2006050501A2 (fr) 2004-11-03 2006-05-11 University Of Kansas Analogues de novobiocine en tant qu'agents anticancereux
CA2590294A1 (fr) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyridopyrimidinones, dihydropyrimidopyrimidinones et pteridinones utiles en tant qu'inhibiteurs des kinases raf
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EP1872922A1 (fr) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Procédé et dispositif de fabrication d'un article en matière plastique
CN104784695A (zh) 2006-08-16 2015-07-22 埃克塞利希斯股份有限公司 使用pi3k和mek调控剂的方法
KR101099926B1 (ko) * 2006-09-15 2011-12-28 화이자 프로덕츠 인코포레이티드 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도
WO2008112913A1 (fr) * 2007-03-14 2008-09-18 Exelixis, Inc. Inhibiteurs de la voie de signalisation du hérisson (voie hedgehog)
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
WO2010039740A1 (fr) * 2008-09-30 2010-04-08 Exelixis, Inc. Inhibiteurs de pyridopyrimidinone de la pi3 kinase α et de la mtor
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療

Also Published As

Publication number Publication date
CN101573358A (zh) 2009-11-04
US8273755B2 (en) 2012-09-25
AP2009004790A0 (en) 2009-04-30
AU2007297212B2 (en) 2011-04-14
IL197243A0 (en) 2009-12-24
KR20090040389A (ko) 2009-04-23
PT2074122E (pt) 2011-08-24
ATE514695T1 (de) 2011-07-15
US20100137279A1 (en) 2010-06-03
AU2007297212B8 (en) 2011-04-28
NZ575167A (en) 2010-10-29
CL2007002682A1 (es) 2008-04-04
BRPI0716749B8 (pt) 2021-05-25
TW200820972A (en) 2008-05-16
SI2074122T1 (sl) 2011-10-28
CU20090040A7 (es) 2011-07-11
UY30588A1 (es) 2008-05-02
BRPI0716749A2 (pt) 2014-02-18
MEP8009A (en) 2011-12-20
NI200900032A (es) 2010-05-14
CR10662A (es) 2009-04-17
WO2008032162A1 (fr) 2008-03-20
CA2663401A1 (fr) 2008-03-20
EA200970207A1 (ru) 2009-08-28
MA30709B1 (fr) 2009-09-01
ES2366489T3 (es) 2011-10-20
DK2074122T3 (da) 2011-08-15
TWI334353B (en) 2010-12-11
US7696213B2 (en) 2010-04-13
AP2710A (en) 2013-07-30
GT200700077A (es) 2009-08-03
JP2010503653A (ja) 2010-02-04
HK1138589A1 (en) 2010-08-27
HRP20110621T2 (hr) 2013-12-06
PL2074122T3 (pl) 2011-10-31
DOP2009000039A (es) 2015-12-15
RS51927B (en) 2012-02-29
AU2007297212A1 (en) 2008-03-20
KR101099926B1 (ko) 2011-12-28
US20080090801A1 (en) 2008-04-17
HN2007000267A (es) 2011-02-25
ZA200901477B (en) 2010-07-28
GEP20115306B (fr) 2011-10-10
EP2074122A1 (fr) 2009-07-01
US20120309775A1 (en) 2012-12-06
MY146420A (en) 2012-08-15
EP2074122B9 (fr) 2013-09-11
DK2074122T5 (da) 2014-03-17
PE20080670A1 (es) 2008-06-14
CA2663401C (fr) 2011-07-12
CN101573358B (zh) 2012-05-30
HRP20110621T1 (en) 2011-09-30
ES2366489T9 (es) 2013-12-27
EP2074122B1 (fr) 2011-06-29
RS20090104A (en) 2010-06-30
NO20091141L (no) 2009-03-31
AR062785A1 (es) 2008-12-03
WO2008032162A8 (fr) 2009-03-26
NO342357B1 (no) 2018-05-14
JP4718637B2 (ja) 2011-07-06
BRPI0716749B1 (pt) 2020-10-06
EA016388B1 (ru) 2012-04-30
US8633204B2 (en) 2014-01-21
MX2009002927A (es) 2009-03-31
CU23783B7 (es) 2012-02-15
CY1111911T1 (el) 2015-11-04
IL197243A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
TN2009000085A1 (fr) Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
CY1118199T1 (el) Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
MA33492B1 (fr) Inhibiteurs de bace
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
EA200970156A1 (ru) Пиридизиноновые производные
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
RS53179B (en) BENZODIAZEPINSKI INHIBITOR BROMODOMENA
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
EA201070480A1 (ru) Ингибиторы с-fms киназы
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.